The emblematic role of ECS in metabolic syndrome and obesity is already known; indeed, the CB1 antagonist rimonabant has been proposed in obesity treatment due to its beneficial effects on both bodyweight and lipid profile. Here, CNR1 is linked to obesity disorder.